Sponsored By

J&J's Biosense Launches New Mapping Catheter

Biosense Webster, a Johnson & Johnson MedTech company, released a new mapping catheter, the Octaray, which has eight splines.

Amanda Pedersen

September 6, 2022

2 Min Read
Untitled design-366.png
Image courtesy of Biosense Webster

A new cardiac mapping catheter, developed by Biosense Webster, could help electrophysiologists map cardiac arrhythmias more accurately and efficiently.

Irvine, CA-based Biosense, part of Johnson & Johnson MedTech, released the Octaray Mapping Catheter with Trueref technology powered by the Carto 3 Version 7 System. The new cardiac mapping catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than the Pentaray Nav Eco Mapping Catheter, which may shorten overall ablation procedure times, according to the company.

The Octaray is designed to map arrhythmias in any chamber and to provide physicians with enhanced clarity, speed, and integration to capture precise information for their catheter ablation procedures. The device is FDA cleared and CE marked.

"With more splines and electrodes, the increased surface area coverage and improved signal quality with the Octaray Mapping Catheter allows me to better understand the anatomy and conduction properties of the chamber of interest," said Amit Thosani, MD, director of cardiac electrophysiology at Allegheny Health Network. "This catheter not only helps me to map more accurately and efficiently, but also allows for better patient specific therapy."

Trueref technology is a mapping reference electrode designed to reduce the impact of farfield signals. The catheter has 48 small mapping electrodes on eight splines, reduced electrode size, and tight electrode spacing. The new cardiac mapping catheter is designed to accurately identify lesion set gaps, and to improve characterization of lesion sets compared to the Pentaray Nav Eco. Biosense said the Octaray catheter allows for mapping with greater precision and detail with improved signal quality.

"I am excited about the addition of the Octaray Mapping Catheter to the suite of tools available to map cardiac arrhythmias at my institution," said Benjamin Berte, MD, co-chief physician and co-head of electrophysiology, Cantonal Hospital of Lucerne, Switzerland. "As the prevalence of patients with AFib continues to rise, physicians need innovative tools to deliver more efficient and effective procedures to benefit their patients."

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like